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Proteoglycans are proteins that carry glycosaminoglycans (GAGs) 1 . The common GAGs are heparin, heparan sulfate (HS), chondroitin sulfate (CS), dermatan sulfate (DS), and hyaluronic acid (HA). These GAGs have a large number of sulfate or carboxyl groups, and hence have a strong negative charge, which makes it possible for proteoglycans to bind, through their GAG chains, various positively charged molecules such as certain growth factors, cytokines, and chemokines (1, 2) . This interaction in the extracellular matrix or on the cell surface has been suggested to play important roles in vivo in the formation of immobilized gradients of these humoral factors, in their protection from proteolytic degradation, and in their presentation to specific cell-surface receptors (3) (4) (5) . There is an increasing body of evidence indicating that HS proteoglycans are particularly important in promoting the oligomerization of chemokines and in facilitating their presentation to specific receptors (6) (7) (8) . Sporadic reports indicate that CS proteoglycans may also have this function (9, 10) . For instance, CS proteoglycans on human neutrophils specifically bind platelet factor 4 (PF-4) and are involved in the activation of neutrophils (9) . An artificial proteoglycan modified with CS binds RANTES via its GAGs, which also induces the activation of T cells expressing this molecule on their surface (10) . Thus, not only HS but also CS proteoglycans appear to bind chemokines and to play important roles in the regulation of chemokine functions.
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After washing, the wells were incubated with streptavidin-conjugated alkaline phosphatase (SA-AP) (1: 500, Promega, Madison, WI) for 1 h. To quantify the reaction, Blue Phos TM (Kirkegaard Perry Laboratories, Gaithersburg, MD) was added, and the optical density was read at 620 nm in a microtiter plate reader (InterMed, Tokyo, Japan). To determine the binding of MCP-1 to versican, versican (20 µg/ml) was coated on 4-mm-diameter 96-well EIA/RIA plates (Costar, Corning Inc.) overnight at 4˚C. The wells were washed with PBS+, and blocked with 3% BSA in PBS+ for 2 h at room temperature. MCP-1 (0-3 µg/ml) was added to the versican-coated wells and incubated for 2 h. After washing, the wells were incubated with biotinylated goat antihuman MCP-1 (1 µg/ml, Santa Cruz, Santa Cruz, CA), and then with peroxidaseconjugated streptavidin in PBS+ containing 0.1% BSA and 0.05% Tween 20 for 1 h at room temperature. To quantify the reaction, o-phenylenediamine (0.4 mg/ml) was used as the substrate and the optical density at 490 nm was read in a microtiter plate reader. In some experiments, immobilized versican was treated with chondroitinase ABC (0.6 U/ml, pH 8.0), chondroitinase B (0.06 U/ml, pH 8.0), or keratanase (0.6 U/ml, pH 8.0) overnight at 37˚C. After blocking, SLC (1 µg/ml) was added to the wells and incubated for 1 h at room temperature. After washing, bound SLC was detected with SA-AP and Blue Phos TM as described above. To examine the efficacy of the enzyme digestion, either mAb 2B1 (3 µg/ml) or CS56 (1: 500 dilutions) was added to the wells after the enzyme treatment. Peroxidase-conjugated anti-mouse IgG or anti-mouse IgG+IgM was then added to detect the binding of the primary antibodies.
The binding was quantified by the o-phenylenediamine reaction as described above. [II] Cell adhesion to MAdCAM-1 induced by SLC that had been immobilized on versican or GAGs was determined as follows. Various combinations of versican (300 ng/well), CS A, CS B, or HS (50 µg/ml) and MAdCAM-1-IgG (100 ng/well) or human IgG (100 ng/well) were co-immobilized in the wells overnight at 4˚C. After blocking with FCS, SLC (0-3 µg/ml) was added to the wells for 2 h at room temperature.
Unbound SLC was removed by washing with PBS. Cell adhesion to each well was determined as described above. cells/ml in PBS+ containing 1% FCS. A 1.5-ml sample of cell suspension was placed in a cuvette and set into a spectrofluorophotometer (RF1500, Shimadzu, Japan) with constant stirring. SLC (1 µg/ml), SDF-1β (1 µg/ml) or leukotriene D4 (Sigma, 0.2 µg/ml) was preincubated with versican (0.1, 0.2 or 0.4 µg/ml) or GAGs (50 µg/ml) for 10 min at room temperature and added to the cell suspension. Emission fluorescence intensity at 510 nm was measured upon excitation at 340 nm (F340) and 380 nm (F380).
Ca
Data were presented as the ratio of F340 divided by F380 (R340/380). After each measurement, R340/380 in the presence or absence of excess calcium was determined by the sequential addition of 100 µl of 1% Triton X-100 with or without 100 µl of 0.5 M EDTA. 
Binding of radiolabeled SLC to CCR7 transfectant cells-The

Results
Versican binds various chemokines
The binding of versican to 18 different chemokines was examined by dot blot analysis. Various chemokines were spotted onto a nitrocellulose membrane, then biotinylated versican was added, and after washing its binding was determined. Antiversican core protein mAb 2B1 and anti-CS mAb CS56 were also spotted on the membrane to serve as positive controls for versican binding. As shown in Fig 1A, biotinylated versican bound the CXC chemokines IP-10, PF-4, and SDF-1β, the C chemokine lymphotactin, and the CC chemokines MCP-1, MCP-2, RANTES, LARC, and SLC. In contrast, biotinylated versican failed to bind IL-8 or MIP-1α, which are known to bind HS (29) (30) (31) .
We then performed a reverse assay where the ability of immobilized versican to bind soluble chemokines was tested by ELISA. As shown in Fig. 1B , versican bound SLC and MCP-1 in a dose-dependent manner. Similarly, immobilized versican also bound SDF-1β and lymphotactin in a dose-dependent manner (data not shown).
Versican binds chemokines in a GAG-dependent manner
To examine whether the chemokine binding is mediated by the GAG chains on versican, the effects of GAG-degrading enzymes on the binding of SLC to versican were examined. As shown in Fig. 2A , both chondroitinase ABC and chondroitinase B inhibited the binding of versican to SLC, while neither of these enzymes affected the reactivity of versican with anti-versican core protein mAb 2B1 (Fig. 2) . In addition, Versican did not affect the LTD4-induced intracellular Ca 2+ response (Fig. 5A ). When
GAGs were used instead of versican, CS B was again inhibitory on SLC-induced intracellular Ca 2+ response, while CS A and HS were not (Fig. 5B) . These results further suggest that versican inhibits the ability of chemokines to elicit intracellular signals, and it does so, at least in part, via its GAG chains.
How does versican inhibit the effects of SLC?
To investigate the mechanism by which versican inhibits chemokine functions, we examined whether versican affects the binding of SLC to CCR7-expressing cells.
As shown in Based on the observations that binding of the CC chemokine SLC to versican was inhibited by chondroitinase B, which specifically cleaves the CS B chain, and that CS B itself bound SLC directly, it is likely that CS B or a GAG containing a CS B-type structure on versican is actually involved in the chemokine binding. This hypothesis is supported by our GAG composition analysis using FACE (fluorophore-assisted carbohydrate electrophoresis) and immunological analysis using anti-GAG mAbs, which indicated that versican is modified with at least CS B and CS C (15). However, we do not know currently whether versican is modified with CS E or a similar moiety, and further structural analysis will be required to understand the exact carbohydrate structure responsible for SLC binding. Thus, versican on its own does not appear to bind to the cells used in this study, and hence, the third possibility seems unlikely. The fourth possibility, that the SLC that is complexed with versican or certain GAGs is unable to transduce an appropriate chemokine signal after binding to CCR7, is currently difficult to exclude and may, at least in part, be involved in the mechanism of inhibition. Consistent with this idea, it was recently reported that soluble complexes of RANTES and GAG chains can bind to an appropriate chemokine receptor but cannot induce intracellular Ca 2+ signaling (35) .
Collectively, the available data suggest that versican/GAG does not inhibit SLC signaling through inhibiting SLC binding to CCR7. Rather, the inhibition of SLC signaling is probably at least partly due to inhibition of the chemokine signal after SLC binds its receptor. Still other possible mechanisms remain to be completely excluded.
Versican binds certain chemokines, but not all of them. It is notable that versican tends to preferentially bind chemokines that attract mononuclear leukocytes.
Preliminary analysis of the amino acid sequences of versican-reactive and non-reactive Given that only specific kinds of GAGs can bind chemokines (Fig. 3) , it is likely that only versican species modified with specific GAGs can bind chemokines.
We previously showed that versican derived from ACHN binds, via its GAG chains, a leukocyte adhesion molecule, L-selectin (14) , and that certain GAGs such as CS B, CS E, and HS bind L-selectin directly (15) . This specificity of binding is quite similar to what we observed for chemokine binding (Fig. 3B) ; i.e., those GAGs that bind Lselectin also bind certain chemokines, and those GAGs that do not bind L-selectin fail to bind the chemokines. Thus, we speculate that versican species modified with Lselectin-reactive GAGs also bind chemokines, which may be of particular importance in 
